|
2019 Journal Article Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBurtness, Barbara, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G. M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Roy, Ananya, Zhang, Yayan, Gumuscu, Burak, Cheng, Jonathan D., Jin, Fan, Rischin, Danny, Lerzo, Guillermo, Tatangelo, Marcelo, Varela, Mirta, Zarba, Juan Jose, Boyer, Michael ... on behalf of the KEYNOTE-048 Investigators (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet, 394 (10212), 1915-1928. doi: 10.1016/S0140-6736(19)32591-7 |
|
2019 Conference Publication Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 studyGrob, J. J., Gonzalez Mendoza, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J., Zhang, P., Gumuscu, B., Swaby, R. F. and Hughes, B. G. M. (2019). Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona Spain, Sep 27-Oct 01, 2019. OXFORD: OXFORD UNIV PRESS. |
|
2019 Conference Publication Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)Rischin, D., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D., Dunn, L. A., Chang, A. L. S., Hauschild, A., Ulrich, C., Eigentler, T., Migden, M. R., Pavlick, A. C., Geiger, J., Stankevich, E., Li, S., Lowy, I., Fury, M. G. and Guminski, A. (2019). Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press. |
|
2019 Journal Article Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNCMoroney, Laura B., Ward, Elizabeth C., Helios, Jennifer, Crombie, Jane, Burns, Clare L., Blake, Claire, Comans, Tracy, Chua, Benjamin, Kenny, Lizbeth and Hughes, Brett G. M. (2019). Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC. Supportive Care in Cancer, 28 (4), 1867-1876. doi: 10.1007/s00520-019-04992-x |
|
2019 Journal Article Traveling with cancer: a guide for oncologists in the modern worldHeng, Sharon, Hughes, Brett, Hibbert, Michael, Khasraw, Mustafa and Lwin, Zarnie (2019). Traveling with cancer: a guide for oncologists in the modern world. Journal of Global Oncology, 5 (5) Y, 1-10. doi: 10.1200/JGO.19.00029 |
|
2019 Conference Publication KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinomaGrob, Jean-Jacques, Gonzalez Mendoza, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica, Grange, Florent, Meyer, Nicolas, Piulats, Josep, Zhang, Pingye (Eric), Gumuscu, Burak, Swaby, Ramona and Hughes, Brett G. M. (2019). KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-CT170 |
|
2019 Journal Article The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancerTurner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Hughes, Brett G. M., McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Paviour, Alana, Skerman, Helen, Batstone, Martin and Mackenzie, Lisa (2019). The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. Supportive Care in Cancer, 27 (12), 4627-4637. doi: 10.1007/s00520-019-04748-7 |
|
2019 Conference Publication Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN)Ahern, Elizabeth Stephanie, Cubitt, Annette, Ballard, Emma, Teng, Michele W.L., Dougall, William C., Smyth, Mark J. and Hughes, Brett Gordon Maxwell (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA United States, 28 February — 2 March 2019. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2019.37.8_suppl.tps129 |
|
2019 Journal Article Patterns of care for stage III non–small cell lung cancer in AustraliaParente, Phillip, Chan, Bryan A., Hughes, Brett G. M., Jasas, Kevin, Joshi, Rohit, Kao, Steven, Hegi-Johnson, Fiona, Hui, Rina, McLaughlin-Barrett, Sara, Nordman, Ina and Stone, Emily (2019). Patterns of care for stage III non–small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 15 (3), 93-100. doi: 10.1111/ajco.13140 |
|
2019 Conference Publication Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC)Wirth, Lori J., Leboulleux, Sophie, Kiyota, Naomi, Tahara, Makoto, Muro, Kei, Ahn, Myung-Ju, Ando, Yuichi, Taylor, Matthew H., Takahashi, Shunji, Kim, Sung-Bae, Misir, Soamnauth, Dutcus, Corina E., Xie, Ran, Joshi, Prashant Ramesh, Hughes, Brett Gordon Maxwell, Aller, Javier, Krzyzanowska, Monika K. and Capdevila, Jaume (2019). Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6081 |
|
2019 Conference Publication Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET stagingSenko, Clare, Moore, Julie, Hay, Karen, Lwin, Zarnie, Pratt, Gary, Fong, Kwun and Hughes, Brett Gordon Maxwell (2019). Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. |
|
2019 Conference Publication Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Baste, Neus, Neupane, Prakash C., Bratland, Ase, Fuereder, Thorsten, Hughes, Brett Gordon Maxwell, Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Zhang, Yayan, Jin, Fan, Gumuscu, Burak and Burtness, Barbara (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6000 |
|
2019 Conference Publication KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC)Grob, Jean Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica Ruth, Grange, Florent, Meyer, Nicolas, Piulats, Josep M., Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett Gordon Maxwell (2019). KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.TPS9598 |
|
2019 Conference Publication Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-upGuminski, Alexander David, Lim, Annette May Ling, Khushalani, Nikhil I., Schmults, Chrysalyne D., Hernandez-Aya, Leonel Fernando, Modi, Badri, Dunn, Lara, Hughes, Brett Gordon Maxwell, Chang, Anne Lynn S., Hauschild, Axel, Migden, Michael Robert, Gutzmer, Ralf, Alam, Murad, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2019). Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.9526 |
|
2018 Journal Article Pembrolizumab as palliative immunotherapy in malignant pleural mesotheliomaMetaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia A., Klingbiel, Dirk, Kao, Steven, Schmid, Sabine, Nowak, Anna K., Gautschi, Oliver, Bartnick, Tammo, Hughes, Brett G., Bouchaab, Hasna, Rothschild, Sacha I., Pavlakis, Nick, Wolleb, Sibylle, Petrausch, Ulf, O'Byrne, Kenneth, Froesch, Patrizia, Löffler-Baumann, Melanie, Pratsch-Peter, Susanne, Russell, Prudence, Mingrone, Walter, Savic, Spasenija, Thapa, Bibhusal, Früh, Martin, Pless, Miklos, von Moos, Roger and John, Thomas (2018). Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13 (11), 1784-1791. doi: 10.1016/j.jtho.2018.08.007 |
|
2018 Conference Publication KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., De Castro, G., Psyrri, A., Rotllan, N. Baste, Neupane, P. C., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. Wan, Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., De Castro, G., Psyrri, A., Baste Rotllan, N., Neupane, P. C., Bratland,, Fuereder, T., Hughes, B. G.M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.045 |
|
2018 Conference Publication Thromboembolism in ROS1 Rearranged Non-Small Cell Lung CancerItchins, M., Alexander, M., John, T., Kao, S., Hughes, B., Hayes, S., Howel, V., Harvie, R., Clarke, S., Millward, M. and Pavlakis, N. (2018). Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jtho.2018.08.1104 |
|
2018 Journal Article Identifying barriers to physical activity in patients with lung cancer: an Australian pilot studyTran, Q., Schimdt, A., Lwin, Z. and Hughes, B. G. M. (2018). Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study. Annals of Oncology, 29, viii756. doi: 10.1093/annonc/mdy424.088 |
|
2018 Journal Article PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaMigden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., Li, J., Mathias, M., Booth, J., Mohan, K., Stankevich, E., Babiker, H. M., Brana, I., Gil-Martin, M., Homsi, J. ... Fury, M. G. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of Medicine, 379 (4), 341-351. doi: 10.1056/NEJMoa1805131 |
